Biocon Limited — Q1 FY24
Biocon Group delivered a strong revenue-led Q1 FY24, with consolidated revenue up 59% YoY to INR 3,516 crore, driven by the Viatris biosimilars acquisition and robust growth acr...
bullish
medium
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
75%Questions answered2Evaded / deflected12Questions auditedContradictedNumbers vs filing
Partial answer
High priority
Pricing environment for biosimilars beyond Fulphila, e.g., Semglee, Ogivri.
Asked by Damayanti Kerai, HSBC
Acknowledged variation but did not quantify pricing trends for specific products.
no specific pricing numbers givengeneralized response
Read the exchange
Question
Can you talk a bit about how we are seeing pricing for other biosimilars, say, Semglee or Ogivri?
Matt Erick, CCO, Biocon Biologics
The pricing that we're seeing in discount trends, they've not been uniform... What we're seeing on the other products, we are seeing very active growth and good growth in those other channels, like Semglee, trastuzumab, et cetera.
Answered
High priority
Pricing pressure on Semglee insulin glargine.
Asked by Damayanti Kerai, HSBC
Directly answered no pricing pressure and explained mix dynamics.
Read the exchange
Question
From Semglee's perspective, did you see any such pricing pressure coming in?
Matt Erick, CCO, Biocon Biologics
As we're seeing it right now, no, there's not that pressure... the mix continues to be in a positive manner that we're seeing with our insulin glargine and Semglee.
Evasive
High priority
Hulio launch update: payer response and market share outlook.
Asked by Damayanti Kerai, HSBC
No specific payer feedback or pricing discussions shared; called it early days.
no concrete updatesdeferred to future
Read the exchange
Question
Post-Hulio launch, can you update us on what you're hearing from payers or what has been their response, and any discussion which is currently ongoing for prices?
Matt Erick, CCO, Biocon Biologics
These are very, very early days, and the payers' landscape is still developing... we're in active discussions with all the payers as this market continues to develop.
Answered
High priority
Reason for sharp decline in core EBITDA margins from 39% to 28%.
Asked by Harith Ahamed, Avendus Spark
Quantified the $15 million rebate impact and explained it was a one-off legacy issue.
Read the exchange
Question
It's at 28% this quarter. I see that it was around 39% last quarter. There's a sharp decline... If you can quantify this impact.
Shreehas Tambe, CEO and Managing Director, Biocon Biologics Limited
We've had a situation with one product where we've had these managed care customer, where the legacy Viatris contracts that we had, had a higher rebate... That was in the region of around $15 million.
Answered
Medium priority
Breakup of Biocon Biologics revenues between regulated and emerging markets.
Asked by Harith Ahamed, Avendus Spark
Provided exact percentage breakdown as requested.
Read the exchange
Question
If you can share the breakup between regulated markets and emerging markets for Biocon Biologics revenues for the quarter.
M.B. Chini, CFO, Biocon Biologics Limited
It's 75% advanced markets, 25% emerging markets.
Evasive
Medium priority
Nature and timing of INR 167 crore licensing income.
Asked by Harith Ahamed, Avendus Spark
Did not clarify if deals were signed this quarter or past; vague on recognition timing.
no specifics on deal timing or geography
Read the exchange
Question
This figure of INR 167 crore, these income pertains to deals that were signed during the quarter, or these are deals that we've partnered in the past?
M.B. Chini, CFO, Biocon Biologics Limited
We saw some of that happening this quarter, and that was the recognition of that INR 167 that you talked about. You will see this happen in a particular quarter. May not necessarily happen in every quarter.
Answered
High priority
Whether the $15 million pegfilgrastim charge is recurring and if similar charges may hit other products.
Asked by Surya Patra, PhillipCapital India
Clearly stated the charge is non-recurring and not expected on other products.
Read the exchange
Question
Is it fair to believe that this is a charge because of the new contract... a similar charge on the product would come in the subsequent period? Also, whether this kind of enhanced rebate can come relating to other products?
Shreehas Tambe, CEO and Managing Director, Biocon Biologics Limited
This is about the past... we've reset these contracts. Going forward, that's why you will not see those things come in... We are not aware of any charge at this point on any other product.
Answered
Medium priority
Clarification on market share metric: prescriptions written vs. filled.
Asked by Surya Patra, PhillipCapital India
Directly clarified that 12% is filled prescriptions and 15% is new prescriptions written.
Read the exchange
Question
When we talk about this market share for any product in the US, is it the total prescription that is really written or it is the prescription that is filled?
Matt Erick, CCO, Biocon Biologics
I think the 12% is the prescriptions filled and the NRXs are prescriptions written. 15% is the trending towards how much extra is being written.
Answered
High priority
Confirmation of mid-30s core margin guidance for FY24 despite one-off rebate.
Asked by Neha Manpuria, Bank of America
Confirmed guidance with a simple 'Yes'.
Read the exchange
Question
We're still holding our mid-thirties guidance for FY 2024, the core margin guidance that we've given for biosimilars?
Kiran Mazumdar-Shaw, Executive Chairperson, Biocon
Yes.
Partial answer
High priority
Timeline for clarity on Hulio volume allocation and market opportunity.
Asked by Neha Manpuria, Bank of America
Gave a broad timeline but no concrete milestones for when clarity will emerge.
no specific timeline for clarity
Read the exchange
Question
When would we get a better sense on what the opportunity could be for Biocon?
Shreehas Tambe, CEO and Managing Director, Biocon Biologics Limited
This decision-making will happen over the course of this calendar year... you will see most of these things really consolidate towards 2025.
Answered
High priority
Sequential run rate for biosimilar segment and Semglee market share aspiration.
Asked by Shyam Srinivasan, Goldman Sachs
Confirmed mid-teens market share guidance for Semglee.
Read the exchange
Question
How should we look at this as we move through the quarters? ...the high teens market share that we were talking about earlier, is that something that's still that we can certainly do?
Shreehas Tambe, CEO and Managing Director, Biocon Biologics Limited
We're still tracking to that mid-teens that we had said, Shyam. I don't think we are moving from that just yet.
Answered
Medium priority
Disaggregation of generics growth into API vs. formulations.
Asked by Shyam Srinivasan, Goldman Sachs
Provided exact revenue split between API and formulations.
Read the exchange
Question
Just on the generics business, I think 15% growth, if you can just help us disaggregate that into what is happening in API versus formulation.
Siddharth Mittal, CEO and Managing Director, Biocon
Formulations business actually touched INR 200 crore this quarter. Out of INR 700 crore, INR 200 crore is formulation, and a little over INR 400 crore is API.
Quantitative claims vs filed numbers
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| Core EBITDA margin 28% for Biocon Biologics this quarter | 28% | 20% | Overstated vs filing |
| Generics revenue INR 700 crore, formulations INR 200 crore, API over INR 400 crore | ₹700 cr | ₹3,423 cr | Understated vs filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.